The development of a bedside algorithm capable of targeting anti- endotoxins to the responder subpopulations

M. C. Birmingham, David E. Nix, T. J. Cumbo, D. A. Collins, P. B. Wels, J. J. Schentag

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The published selection criteria for use of anti-endotoxin antibodies are modeled on the criteria used in protocol enrollment of patients. These criteria are not suitable for therapeutic decision-making, because the trials themselves prove that the enrollment criteria have both low sensitivity and low specificity. In order to develop a selection method with greater sensitivity and specificity, we examined the charts and records of 23 patients that we enrolled in the multicenter trials of E5 and HA-1A. We retrospectively determined that seven of our 23 enrolled patients were optimal candidates, based on a pattern of rapid clinical deterioration followed by improvement in 24-96 h. We then explored a variety of different modes of bedside patient selection, in search of a method to select as many of the seven optimal candidates as possible while at the same time rejecting the greatest number of the 16 who showed no benefit when treated. None of the resulting selection methods has perfect performance, but nearly all were better than the original protocol enrollment criteria. In our patients, bacteremia had 57% sensitivity and 56% specificity, which was quite similar to the findings in the HA-1A multicenter trial. Shock had 100% sensitivity and 44% specificity, while a baseline organ dysfunction score of ≥5 had 100% sensitivity and 69% specificity. A new algorithm that we developed based on a patient's need for vasopressors and baseline organ dysfunction had 100% sensitivity and 81% specificity. This algorithm could identify all seven of the optimal candidates, plus three more. We propose that there are bedside methods capable of considerably more specific identification of patients who would respond to treatment with anti-endotoxin antibodies.

Original languageEnglish (US)
Pages (from-to)503-509
Number of pages7
JournalTherapeutic Drug Monitoring
Volume15
Issue number6
StatePublished - 1993
Externally publishedYes

Fingerprint

Endotoxins
Sensitivity and Specificity
Deterioration
Decision making
Patient Selection
Multicenter Studies
Organ Dysfunction Scores
Bacteremia
antilipopolysaccharide antibodies
Shock
Decision Making
Therapeutics

Keywords

  • Anti-endotoxin antibodies
  • Bedside algorithm
  • Clinical trials
  • Selection criteria

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Pharmacology
  • Toxicology

Cite this

Birmingham, M. C., Nix, D. E., Cumbo, T. J., Collins, D. A., Wels, P. B., & Schentag, J. J. (1993). The development of a bedside algorithm capable of targeting anti- endotoxins to the responder subpopulations. Therapeutic Drug Monitoring, 15(6), 503-509.

The development of a bedside algorithm capable of targeting anti- endotoxins to the responder subpopulations. / Birmingham, M. C.; Nix, David E.; Cumbo, T. J.; Collins, D. A.; Wels, P. B.; Schentag, J. J.

In: Therapeutic Drug Monitoring, Vol. 15, No. 6, 1993, p. 503-509.

Research output: Contribution to journalArticle

Birmingham, MC, Nix, DE, Cumbo, TJ, Collins, DA, Wels, PB & Schentag, JJ 1993, 'The development of a bedside algorithm capable of targeting anti- endotoxins to the responder subpopulations', Therapeutic Drug Monitoring, vol. 15, no. 6, pp. 503-509.
Birmingham, M. C. ; Nix, David E. ; Cumbo, T. J. ; Collins, D. A. ; Wels, P. B. ; Schentag, J. J. / The development of a bedside algorithm capable of targeting anti- endotoxins to the responder subpopulations. In: Therapeutic Drug Monitoring. 1993 ; Vol. 15, No. 6. pp. 503-509.
@article{42c838f12b404aa6a5c5943a530e40a8,
title = "The development of a bedside algorithm capable of targeting anti- endotoxins to the responder subpopulations",
abstract = "The published selection criteria for use of anti-endotoxin antibodies are modeled on the criteria used in protocol enrollment of patients. These criteria are not suitable for therapeutic decision-making, because the trials themselves prove that the enrollment criteria have both low sensitivity and low specificity. In order to develop a selection method with greater sensitivity and specificity, we examined the charts and records of 23 patients that we enrolled in the multicenter trials of E5 and HA-1A. We retrospectively determined that seven of our 23 enrolled patients were optimal candidates, based on a pattern of rapid clinical deterioration followed by improvement in 24-96 h. We then explored a variety of different modes of bedside patient selection, in search of a method to select as many of the seven optimal candidates as possible while at the same time rejecting the greatest number of the 16 who showed no benefit when treated. None of the resulting selection methods has perfect performance, but nearly all were better than the original protocol enrollment criteria. In our patients, bacteremia had 57{\%} sensitivity and 56{\%} specificity, which was quite similar to the findings in the HA-1A multicenter trial. Shock had 100{\%} sensitivity and 44{\%} specificity, while a baseline organ dysfunction score of ≥5 had 100{\%} sensitivity and 69{\%} specificity. A new algorithm that we developed based on a patient's need for vasopressors and baseline organ dysfunction had 100{\%} sensitivity and 81{\%} specificity. This algorithm could identify all seven of the optimal candidates, plus three more. We propose that there are bedside methods capable of considerably more specific identification of patients who would respond to treatment with anti-endotoxin antibodies.",
keywords = "Anti-endotoxin antibodies, Bedside algorithm, Clinical trials, Selection criteria",
author = "Birmingham, {M. C.} and Nix, {David E.} and Cumbo, {T. J.} and Collins, {D. A.} and Wels, {P. B.} and Schentag, {J. J.}",
year = "1993",
language = "English (US)",
volume = "15",
pages = "503--509",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The development of a bedside algorithm capable of targeting anti- endotoxins to the responder subpopulations

AU - Birmingham, M. C.

AU - Nix, David E.

AU - Cumbo, T. J.

AU - Collins, D. A.

AU - Wels, P. B.

AU - Schentag, J. J.

PY - 1993

Y1 - 1993

N2 - The published selection criteria for use of anti-endotoxin antibodies are modeled on the criteria used in protocol enrollment of patients. These criteria are not suitable for therapeutic decision-making, because the trials themselves prove that the enrollment criteria have both low sensitivity and low specificity. In order to develop a selection method with greater sensitivity and specificity, we examined the charts and records of 23 patients that we enrolled in the multicenter trials of E5 and HA-1A. We retrospectively determined that seven of our 23 enrolled patients were optimal candidates, based on a pattern of rapid clinical deterioration followed by improvement in 24-96 h. We then explored a variety of different modes of bedside patient selection, in search of a method to select as many of the seven optimal candidates as possible while at the same time rejecting the greatest number of the 16 who showed no benefit when treated. None of the resulting selection methods has perfect performance, but nearly all were better than the original protocol enrollment criteria. In our patients, bacteremia had 57% sensitivity and 56% specificity, which was quite similar to the findings in the HA-1A multicenter trial. Shock had 100% sensitivity and 44% specificity, while a baseline organ dysfunction score of ≥5 had 100% sensitivity and 69% specificity. A new algorithm that we developed based on a patient's need for vasopressors and baseline organ dysfunction had 100% sensitivity and 81% specificity. This algorithm could identify all seven of the optimal candidates, plus three more. We propose that there are bedside methods capable of considerably more specific identification of patients who would respond to treatment with anti-endotoxin antibodies.

AB - The published selection criteria for use of anti-endotoxin antibodies are modeled on the criteria used in protocol enrollment of patients. These criteria are not suitable for therapeutic decision-making, because the trials themselves prove that the enrollment criteria have both low sensitivity and low specificity. In order to develop a selection method with greater sensitivity and specificity, we examined the charts and records of 23 patients that we enrolled in the multicenter trials of E5 and HA-1A. We retrospectively determined that seven of our 23 enrolled patients were optimal candidates, based on a pattern of rapid clinical deterioration followed by improvement in 24-96 h. We then explored a variety of different modes of bedside patient selection, in search of a method to select as many of the seven optimal candidates as possible while at the same time rejecting the greatest number of the 16 who showed no benefit when treated. None of the resulting selection methods has perfect performance, but nearly all were better than the original protocol enrollment criteria. In our patients, bacteremia had 57% sensitivity and 56% specificity, which was quite similar to the findings in the HA-1A multicenter trial. Shock had 100% sensitivity and 44% specificity, while a baseline organ dysfunction score of ≥5 had 100% sensitivity and 69% specificity. A new algorithm that we developed based on a patient's need for vasopressors and baseline organ dysfunction had 100% sensitivity and 81% specificity. This algorithm could identify all seven of the optimal candidates, plus three more. We propose that there are bedside methods capable of considerably more specific identification of patients who would respond to treatment with anti-endotoxin antibodies.

KW - Anti-endotoxin antibodies

KW - Bedside algorithm

KW - Clinical trials

KW - Selection criteria

UR - http://www.scopus.com/inward/record.url?scp=0027438064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027438064&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 503

EP - 509

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 6

ER -